ShapeShapeauthorShapechevroncrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShaperssShape

Ferd backs Benchmark

13 March 2019, at 1:00am

Ferd, the Norwegian investment company, believes that Benchmark Holdings “is uniquely positioned to contribute with sustainable and cost efficient solutions for improving fish health across aquaculture species.”

Following equity issues and market transactions, Ferd now owns 26 percent of Benchmark.

The company says Benchmark occupies:

  • “A leading global position within sales of specialised feed and health products for shrimp and seabass / seabream through the subsidiary INVE. Benchmark delivers starter feeds for hatcheries, where there are particularly high quality requirements for growing robust fish.”
  • “A leading global position with salmonid breeding and genetics, through the subsidiaries Salmobreed and Stofnfiskur, where advanced genetic selection is applied in order to pick individuals that grow fast and are resistant to particular biological challenges such as sea lice. Within breeding and genetics, Benchmark has recently expanded into the market for tilapia and shrimp.”
Benchmark's vaccine production facility in Essex
Benchmark's vaccine production facility in Essex
  • “A major effort in developing treatments and vaccines. Benchmark has for many years sold the Salmosan sea lice treatment, and has since 2011 invested heavily into developing a pipeline of vaccines and for the construction of a state-of-the-art vaccine production facility. Benchmark launched its first in-house developed vaccine in 2016, and several launches are expected in the years to come targeting some of the largest challenges within aquaculture.”